cell - 医索

找到约 332 条结果

Managing Expectations WithAntibody-Drug Conjugates in Non-Small Cell Lung Cancer

医客学院 - 会议报告集

Lorlatinib vs Crizotinib in Treatment-NaivePatients With Advanced ALK Non-SmallCell Lung Cancer 5-Year Progression-FreeSurvival and Safety From the CRoWN Study

医客学院 - 会议报告集

Lorlatinib in TKl naive, advanced RoS1-positivenon-small cell lung cancer a multicenter, open-label, single-arm, phase 2 trial

医客学院 - 会议报告集

Ivonescimab combined with chemotherapy in patientswith EGFR-mutant non-squamous non-small cell lungcancer who progressed on EGFR-TKls treatment arandomized, double-blind, multi-center, phase 3 trial(HARM

医客学院 - 会议报告集

EFFICACY AND SAFETY OF TALETRECTINIB INPATIENTS WITH ADVANCED OR METASTATICROS1 NON-SMALL CELL LUNG CANCER THEPHASE 2 TRUST-I STUDY

医客学院 - 会议报告集

Can We Enhance the Benefit ofImmunotherapy in Non-Small CelLung Cancer

医客学院 - 会议报告集

BEAT-SC A randomized phase lll study ofbevacizumab or placebo in combination withatezolizumab and platinum-based chemotherapy inpatients with extensive-stage small cell lung cancer

医客学院 - 会议报告集

Amivantamab plus lazertinib vs osimertinib infirst-line EGFR-mutant advanced non-small cell lungcancer(NSCLC)with biomarkers of high-risk diseaseA secondary analysis from the phase 3 MARIPOSA study

医客学院 - 会议报告集

Amivantamab plus lazertinib in atypical EGFR-mutatedadvanced non-small cell lung cancer (NSCLC)Results from CHRYSALIS-2

医客学院 - 会议报告集

Adjuvant icotinib of 12 months or 6 months versus observationfollowing adjuvant chemotherapy for resected EGFR-mutatedstage ll-lllA non-small-cell lung cancer (ICTAN, GASTO1002) arandomized phase 3 trial

医客学院 - 会议报告集

今日实时热搜